Brodalumab Shows Rapid and Sustained Efficacy for Treating Psoriasis
In a recent study conducted in Italy, brodalumab, a fully human anti-interleukin (IL)-17 monoclonal antibody, has demonstrated rapid and sustained efficacy in the treatment of adult patients with moderate-to-severe plaque psoriasis who are eligible for systemic treatment.
The study evaluated the therapeutic response of patients treated with brodalumab over a one-year period in the Italian clinical practice. It included 184 eligible patients, found that 64.7% of patients reached an absolute Psoriasis Area and Severity Index (PASI) score of ≤3 at week 12 and maintained this response through week 52. Additionally, 72.7% of patients achieved a PASI 75 response at week 12, with the percentages increasing to 92.9% at week 52. Notably, PASI 90 and PASI 100 responses were achieved by 54.5% and 42.0% of patients at week 12, respectively, and improved to 84.4% and 61.7% at week 52.
Furthermore, the study revealed that a static Physician's Global Assessment (sPGA) score of 0, indicating clear or almost clear skin, was obtained by 55.0% of patients after 12 weeks of treatment and by 77.0% after 52 weeks. Additionally, a Dermatology Life Quality Index (DLQI) score of ≤1, indicating minimal impact on quality of life, was reported by 71.9% of patients after 12 weeks and by 89.9% after 52 weeks of treatment.
Importantly, no significant differences in treatment outcomes were observed among patient subgroups based on their previous antipsoriatic treatments, whether they were biologic-naïve or had prior experience with other treatments.
These findings highlight the effectiveness of brodalumab in improving skin lesions and overall quality of life for patients with moderate-to-severe psoriasis. The study demonstrates that brodalumab rapidly and consistently achieves positive treatment outcomes, making it a promising option for individuals seeking relief from the burdensome symptoms of psoriasis.
It is important to note that brodalumab's safety profile in this study was found to be favorable. However, patients considering brodalumab or any other treatment should consult with their healthcare provider to evaluate its appropriateness and potential risks based on their individual circumstances.
Reference:
Dapavo, P., Fabbrocini, G., Campione, E., Giofrè, C., Balato, A., Potenza, C., Dastoli, S., Malagoli, P., De Pasquale, R., Bonifati, C., Amerio, P., … Fargnoli, M. C. (2023). Achievement and maintenance of therapeutic response to brodalumab in patients with moderate‐to‐severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study). In JEADV Clinical Practice. Wiley. https://doi.org/10.1002/jvc2.204
